In line with the corporate’s regulatory submitting, the authorized product is an antimetabolite immunosuppressant used for the prophylaxis of organ rejection in grownup and pediatric sufferers aged three months and older present process kidney, coronary heart, or liver transplants. The treatment is run together with different immunosuppressive therapies.
The corporate highlighted that the approval aligns with its long-term progress technique and is anticipated to strengthen its presence within the U.S. pharmaceutical market. Business estimates counsel that the U.S. marketplace for Mycophenolate Mofetil is valued at roughly US$30 million, offering Harmony Biotech with a big business alternative.
In its disclosure, Harmony Biotech said that the approval was granted by the U.S. Meals and Drug Administration (USFDA) and pertains particularly to Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. The corporate famous that the approval will improve its product portfolio and assist growth throughout each U.S. and worldwide markets. There have been no situations of withdrawal, cancellation, or suspension of the approval, and due to this fact no related penalties or hostile monetary impression.
Inventory Efficiency and Valuation
Regardless of Tuesday’s rally, Harmony Biotech’s inventory stays considerably beneath its 52-week excessive of Rs 2,150. The inventory’s 52-week low stands at Rs 987. The corporate at the moment instructions a market capitalization of roughly Rs 12,200 crore.
On the valuation entrance, the inventory is buying and selling at a price-to-earnings (P/E) ratio of 42.56 and a price-to-book (P/B) ratio of 6.13.
Technical Indicators
The inventory’s Relative Energy Index (RSI-14) stands at 56.2, indicating neutral-to-positive momentum. An RSI studying beneath 30 is mostly thought-about oversold, whereas a studying above 70 alerts overbought situations.
From a development perspective, Harmony Biotech is buying and selling above six of its eight key easy transferring averages (SMAs), reflecting a broadly optimistic technical setup.
Shareholding Sample
Institutional investor exercise remained blended in the course of the March 2026 quarter. International Institutional Traders (FIIs) marginally elevated their stake in Harmony Biotech to 7.79% from 7.58% within the earlier quarter, reflecting continued investor curiosity. In distinction, mutual funds trimmed their holdings, lowering their stake from 4.44% to 4.30% throughout the identical interval.
(Disclaimer: Suggestions, recommendations, views and opinions given by the specialists are their very own. These don’t characterize the views of The Financial Occasions)
